Nymox Pharmaceutical Corp. (NYMX)

2.25
0.16 6.60
NASDAQ : Health Technology
Prev Close 2.41
Open 2.40
Day Low/High 2.25 / 2.40
52 Wk Low/High 1.25 / 4.60
Volume 46.67K
Avg Volume 82.60K
Exchange NASDAQ
Shares Outstanding 63.72M
Market Cap 165.03M
EPS -0.30
Div & Yield N.A. (N.A)
Nymox Reports 2012 Financial Results

Nymox Reports 2012 Financial Results

4 Biotech Stocks Under $10 Moving Higher

4 Biotech Stocks Under $10 Moving Higher

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Biotech Stock Mailbag: Amarin or Arena Takeout?

Biotech Stock Mailbag: Amarin or Arena Takeout?

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.

Biotech Stock Mailbag: Sangamo Biosciences

Biotech Stock Mailbag: Sangamo Biosciences

Biotech columnist Adam Feuerstein answers readers' questions and concerns about health care and drug-related stocks.

Nymox Reports 2010 Financial Results

Nymox Reports 2010 Financial Results

Biotech Mailbag: BIO CEO Wrap

Biotech Mailbag: BIO CEO Wrap

Biotech columnist Adam Feuerstein answers readers' questions and concerns about health care and drug-related stocks.

Nymox: Another Look at Enlarged-Prostate Drug

Nymox: Another Look at Enlarged-Prostate Drug

Nymox has more data on its enlarged prostate drug as it progresses through phase III studies but lack of transparency is still a big risk.

TheStreet Quant Rating: E+ (Sell)